An Assessment of Heart-Valve Abnormalities in Obese Patients Taking Dexfenfluramine, Sustained-Release Dexfenfluramine, or Placebo

Authors:
  • JTJohn F. Jr. Tighe
    John F. Jr. Tighe
  • JGJohn S. Gottdiener
    John S. Gottdiener
  • JGJohn T. Gwynne
    John T. Gwynne

Abstract
The appetite-suppressant drug fenfluramine, usually given in combination with phentermine, has been reported to be associated with cardiac valvular regurgitation. Concern has been raised that the d-enantiomer of fenfluramine, dexfenfluramine, may also cause this problem. We were able to study the question by modifying an ongoing trial comparing sustained-release dexfenfluramine with regular dexfenfluramine and placebo.

This publication has 15 references indexed in Scilit: